Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin’s KRN23 Gets BT Designation for X-Linked Hypophosphatemia in Children
Kyowa Hakko Kirin said on June 28 that the US FDA has granted breakthrough therapy designation to KRN23, an investigational anti-FGF23 monoclonal IgG1 antibody, for the treatment of X-linked hypophosphatemia (XLH) in pediatric patients aged one year and older. The…
To read the full story
Related Article
- Kyowa Kirin Begins Global KRN23 PIII for Pediatric X-Linked Hypophosphatemia
October 28, 2016
- Kyowa Kirin Ties Up with Ultragenyx for XLH Treatment KRN23
September 5, 2013
BUSINESS
- Will Unlisted AGs Rush for June Listing or Be Left on Ice?
January 23, 2026
- Enhertu Reels in 6th China Indication in Second-Line Gastric Cancer
January 23, 2026
- Maruho Out-Licenses Rapifort to Taiwan’s Orient EuroPharma
January 23, 2026
- Towa to Take Over Manufacturing of Otsuka’s LLPs in Cross-Sector Tie-Up
January 22, 2026
- Otsuka/Ionis’ HAE Drug Dawnzera Approved in Europe
January 22, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…